바이오로직스 자료
BIO Digital 2021 | A Conversation with Samsung Biologics from a CDMO Point of View
Post-pandemic, from integrated pharmaceutical giants to small biotechs, companies of all sizes view CDMO partnership as essential part of their drug development strategy to augment their capacity & expertise and ultimately reduce time to market. And the CDMOs are trying to adapt to new market dynamics where speed and efficiency are critical to long term success. This fireside chat will demonstrate how Samsung Biologics is delivering unique values to the clients and also highlight on critical success factors in the partnership while the industry continues to evolve.
Post-pandemic, from integrated pharmaceutical giants to small biotechs, companies of all sizes view CDMO partnership as essential part of their drug development strategy to augment their capacity & expertise and ultimately reduce time to market. And the CDMOs are trying to adapt to new market dynamics where speed and efficiency are critical to long term success. This fireside chat will demonstrate how Samsung Biologics is delivering unique values to the clients and also highlight on critical success factors in the partnership while the industry continues to evolve.
